Avantor, Inc. (NYSE: AVTR) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.84 | Insider Own | 1.92% | Shs Outstand | 676.36M | Perf Week | 4.79% |
| Market Cap | 10.50B | Forward P/E | 17.57 | EPS next Y | 0.88 | Insider Trans | 0.27% | Shs Float | 657.88M | Perf Month | 11.17% |
| Enterprise Value | 13.89B | PEG | 0.37 | EPS next Q | 0.21 | Inst Own | - | Short Float | 7.63% | Perf Quarter | 62.00% |
| Income | -578.39M | P/S | 1.60 | EPS this Y | 196.76% | Inst Trans | - | Short Ratio | 5.31 | Perf Half Y | 103.94% |
| Sales | 6.56B | P/B | 1.86 | EPS next Y | 8.71% | ROA | -4.98% | Short Interest | 50.21M | Perf YTD | 35.43% |
| Book/sh | - | P/C | 17.58 | EPS next 5Y | 8.47% | ROE | -10.34% | 52W High | 16.05 -3.30% | Perf Year | 25.16% |
| Cash/sh | - | P/FCF | 23.09 | EPS past 3/5Y | - | ROIC | -2.79% | 52W Low | 7.27 113.48% | Perf 3Y | -27.31% |
| Dividend Est. | - | EV/EBITDA | 110.84 | Sales past 3/5Y | -4.46% 0.49% | Gross Margin | 31.83% | Volatility | 2.87% 2.93% | Perf 5Y | -63.34% |
| Dividend TTM | - | EV/Sales | 2.12 | EPS Y/Y TTM | -180.77% | Oper. Margin | -4.35% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.18 | Sales Y/Y TTM | -3.29% | Profit Margin | -8.81% | RSI (14) | 64.86 | Recom | 2.77 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.78 | EPS Q/Q | -12.50% | SMA20 | 4.23% | Beta | 0.93 | Target Price | 11.67 |
| Payout | 0.00% | Debt/Eq | 0.66 | Sales Q/Q | 0.53% | SMA50 | 14.69% | Rel Volume | 1.57 | Prev Close | 15.86 |
| Employees | 13,500 | LT Debt/Eq | 0.70 | Earnings | Nov 04 | SMA200 | 47.28% | Avg Volume | 9.44M | Price | 15.52 |
| IPO Date | May 17, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.65% 5.07% | Net Debt/EBITDA | 27.06 | Volume | 14,824,591 | Change | -2.14% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Neutral | $8.00 → $16 |
| Jul-30-26 | Reiterated | Deutsche Bank | Hold | $11 → $13 |
| Jul-30-26 | Reiterated | Morgan Stanley | Equal Weight | $10 → $14 |
| Jul-30-26 | Reiterated | RBC Capital | Sector Perform | $9.00 → $14 |
| Jul-29-26 | Reiterated | Jefferies | Underperform | $8.00 → $13 |
| Jul-06-26 | Reiterated | Evercore ISI Group | In Line | $10 → $11 |
| Jun-26-26 | Resumed | Bernstein | Market Perform | $25 → $11 |
| Jun-24-26 | Reiterated | UBS | Neutral | $7.00 → $8.00 |
| Jun-01-26 | Reiterated | Wolfe Research | $7.00 | |
| May-14-26 | Resumed | RBC Capital | Sector Perform | $9.00 |
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,561 | 6,552 | 6,784 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4,473 | 4,413 | 4,504 | — | — | — | — | — | — | |
| Gross Profit | 2,089 | 2,139 | 2,279 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,197 | 1,596 | 1,641 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 1,177 | 790 | -446 | — | — | — | — | — | — | |
| Operating Income | -286 | -246 | 1,085 | — | — | — | — | — | — | |
| Interest Expense | 178 | 170 | 219 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -7 | -25 | -12 | — | — | — | — | — | — | |
| Net Income Before Taxes | -471 | -441 | 854 | — | — | — | — | — | — | |
| Income Taxes | 105 | 89 | 142 | — | — | — | — | — | — | |
| Consolidated Net Income | -579 | -530 | 712 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -579 | -530 | 712 | — | — | — | — | — | — | |
| Net Income | -579 | -530 | 712 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.84 | -0.78 | 1.05 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.84 | -0.78 | 1.05 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.84 | -0.78 | 1.04 | — | — | — | — | — | — | |
| EBITDA | 125 | 139 | 1,478 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 20.26 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.60 | 1.19 | 2.11 | — | — | — | — | — | — | |
| Gross Margin | 31.84 | 32.65 | 33.59 | — | — | — | — | — | — | |
| Operating Margin | -4.36 | -3.75 | 15.99 | — | — | — | — | — | — | |
| Net Margin | -8.82 | -8.09 | 10.50 | — | — | — | — | — | — | |
| Shares Outstanding | 676 | 678 | 680 | — | — | — | — | — | — | |
| Market Capitalization | 10,492 | 7,770 | 14,328 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| LUCIER GREGORY T | Director | May 08 '26 | Buy | 8.32 | 10,000 | 83,200 | 60,000 | May 11 |
| Dingemans Simon | Director | May 01 '26 | Buy | 8.14 | 25,000 | 203,500 | 25,000 | May 05 |
| MEHRA SANJEEV K | Director | Mar 10 '26 | Buy | 8.01 | 125,000 | 1,001,250 | 475,000 | Mar 11 |
| LUCIER GREGORY T | Director | Feb 19 '26 | Buy | 9.16 | 50,000 | 458,000 | 50,000 | Feb 23 |
| SUMME GREGORY L | Director | Feb 12 '26 | Buy | 9.40 | 100,000 | 940,000 | 400,000 | Feb 12 |
| MEHRA SANJEEV K | Director | Dec 05 '25 | Buy | 11.09 | 350,000 | 3,881,500 | 350,000 | Dec 09 |
| Ligner Emmanuel | President and CEO | Nov 17 '25 | Buy | 11.35 | 87,500 | 993,125 | 283,424 | Nov 17 |
| SUMME GREGORY L | Director | Oct 30 '25 | Buy | 11.25 | 100,000 | 1,125,000 | 300,000 | Oct 31 |
| SUMME GREGORY L | Director | Aug 21 '25 | Buy | 12.56 | 100,000 | 1,256,000 | 200,000 | Aug 22 |
| Eck Steven W | SVP & Chief Accounting Officer | Aug 05 '25 | Sale | 11.39 | 3,476 | 39,592 | 55,068 | Aug 06 |
| SUMME GREGORY L | Director | May 23 '25 | Buy | 12.50 | 30,000 | 375,000 | 100,000 | May 27 |
| SUMME GREGORY L | Director | May 22 '25 | Buy | 12.65 | 20,000 | 253,000 | 70,000 | May 22 |
| SUMME GREGORY L | Director | May 07 '25 | Buy | 12.00 | 25,000 | 300,000 | 50,000 | May 09 |
| Massaro Joseph R | Director | Apr 29 '25 | Buy | 12.30 | 8,100 | 99,630 | 35,038 | Apr 29 |
| SUMME GREGORY L | Director | Apr 28 '25 | Buy | 12.50 | 25,000 | 312,500 | 25,000 | Apr 29 |